BioAdaptives, Inc. (OTC: BDPT) announced that MyndRenew(TM), the nighttime component of its MyndSystem(TM) cognitive health platform, has received TruShield Certified status. This certification confirms compliance with anti-doping standards established by the World Anti-Doping Agency (WADA) and the UFC. Combined with the previously certified MyndMed(TM) daytime formula, the company said MyndSystem(TM) is now a fully WADA-compliant 24/7 cognitive performance and recovery system for professional athletes.
The certification strengthens BioAdaptives' position in the sports nutrition market by supporting potential adoption among professional athletes. The company also targets executives and active seniors as key demographics. According to the press release, this milestone could enhance commercialization opportunities, strategic partnerships, and broader market adoption as it expands the MyndSystem(TM) platform. Full details are available at https://ibn.fm/JNHRs.
BioAdaptives develops and markets science-based health and wellness products for humans and animals. Its formulations are grounded in published research on nutrition, adaptogens, and cellular health, with a focus on supporting normal physiological function. More information is available at www.bioadaptives.com.
The certification is significant because it removes a key barrier for athletes who require assurance that supplements do not contain prohibited substances. With both MyndMed(TM) and MyndRenew(TM) certified, the MyndSystem(TM) offers a complete daily regimen that athletes can trust. This could open doors to partnerships with sports organizations, teams, and individual athletes seeking cognitive support without risking anti-doping violations.
For BioAdaptives, the certification represents a strategic milestone in a competitive market. The company's focus on cognitive health addresses growing demand among athletes and aging populations. By achieving full WADA compliance, BioAdaptives differentiates its products in a sector where trust and regulatory adherence are paramount. The news may also attract investors looking for companies with validated products and clear market positioning.
BioMedWire, the source of this press release, is a communications platform focused on biotechnology, biomedical sciences, and life sciences. It is part of the Dynamic Brand Portfolio @IBN, which provides wire solutions, editorial syndication, press release enhancement, and social media distribution. For more information, visit https://www.BioMedWire.com.
